@article {Agarwal2020.09.03.20187252, author = {Anup Agarwal and Aparna Mukherjee and Gunjan Kumar and Pranab Chatterjee and Tarun Bhatnagar and Pankaj Malhotra and PLACID Trial Collaborators}, editor = {Agarwal, Anup and Mukherjee, Aparna and Kumar, Gunjan and Chatterjee, Pranab and Bhatnagar, Tarun and Malhotra, Pankaj and Latha, B and Bundas, Sunita and Kumar, Vivek and Dosi, Ravi and Khambholja, Janakkumar R and de Souza, Rosemarie and Mesipogu, Raja Rao and Srivastava, Saurabh and Dube, Simmi and Chaudhary, Kiran and Subash, S and Mattuvar K, S. Anbuselvi and Rajendran, V and Sundararajaperumal, A and Balamanikandan, P and Maheswari, R S Uma and Jayanthi, R and Ragunanthanan, S and Bhandari, Sudhir and Singh, Ajeet and Pal, Ashok and Handa, Anjali and Rankawat, Govind and Kargirwar, Ketan and Regi, Joyce and Rathod, Darshana and Pathrose, Edwin and Bhutaka, Nirankar and Patel, Mayur H and Verma, Rahul J and Malukani, Kamal and Patel, Shivani and Thakur, Apurv and Joshi, Satish and Kulkarni, Rashmi and Suthar, Nilay N and Shah, Nehal M and Purohit, Hemang M and Shah, Cherry K and Patel, Monila N and Shah, Sanket and Shah, Smit H and Memon, Tehsim and Beriwala, Vishal R and Jashnani, Kusum and Ezzy, Fatema and Agrawal, Simran and Bhadade, Rakesh and Atish, MN and Madke, Tushar and Kavishwar, Vikash and Waghmare, Ramesh and Valvi, Nitin and Chander, B Thrilok and Sekhar, A Vinaya and Maurya, Akhilesh Kumar and Hemanth, K and Nagamani, K and Sudha, K and Chandra, T Ravi and Rao, K Tushara and Vyshnavi, J and Upadhyay, Rashmi and Bahadur, Shalini and Pathak, Rambha and Seth, Shikha and Gupta, Brig. Rakesh and Saxena, Rita and Dwivedi, Preksha and Malik, Reeni and Chourasia, Deepti and Lalwani, Jaya and Sharma, UM and Marko, JL and Suri, Amit and Kumar, Vijay and Kaushik, Rajnish and Kodan, Parul and Acharya, Bhabani Prasad and Gaur, Kuldeep Kumar and Gupta, Anubhav and Sachdeva, Prerna and Dogra, Shruti and Jindal, Aikaj and John, M Joseph and Dhanju, Avtar Singh and Khetrepal, Ranjana and Sharma, Neeraj and Kukar, Neetu and Kavita, Divya and Kumar, Rajesh and Mahajan, Rajesh and Singh, Gurpreet and Kaur, Jaspreet and Singh, Raminder Pal and Bassi, Rajni and Parikh, Swapneil and Shrivastav, Om and Shastri, Jayanthi and Desai, Maherra and Udupa, Shreevatsa and Bafna, Varun A and Barge, Vijay and Madane, Rajendra and Yadav, Sheetal and Mishra, Sanjeev and Bajpayee, Archana and Garg, MK and Bohra, GK and Nag, Vijaylakshmi and Anne, Puneeth Babu and Nadeem, Mohd. and Singh, Pallavi and Niwas, Ram and Khaire, Niranjan S and Sharma, Rattiram and Singh, Mini P and Sachdeva, Naresh and Sachdev, Suchet and Hans, Rekha and Sun, Vikas and Yaddanapudi, L N and Lakshmi, PVM and Singh, Neha and Bhushan, Divendu and Kumar, Neeraj and Tambe, Muralidhar and Salvi, Sonali and Kadgi, Nalini and Sangle, Shashikala and Nakate, Leena and Joshi, Samir and Karyakarte, Rajesh and Goyanka, Suraj and Sharma, Nimisha and Verma, Nikhil and Das, Asim and Bahl, Monika and Wadhwa, Nitya and Bhat, Shreepad and Deshmukh, Shweta and Wagh, Vrushali and Kulkarni, Atul and Yardi, Tanvi and Kaulgud, Ram S and Reddy, Purushottam and Yevoor, Kavitha and Gajula, Prashanth and Maleyur, Vivek and Medini, S and Mohith, HN and Gurtoo, Anil and Sud, Ritika and Pahuja, Sangeeta and Prakash, Anupam and Gogoi, Parijat and Shukla, Shailja and Reddy, D Himanshu and Tulika, Chandra and Pandey, Saurabh and Maurya, Pradeep and Wahid, Ali and Kumar, Vivek and Upadhyay, Kamlesh and Bhatnagar, Nidhi and Shah, Nilima and Shah, Mamta and Patel, Tarak and Jaiswal, Ram Mohan and Jain, Ashish and Sharma, Shweta and Rijhwani, Puneet and Gupta, Naveen and Patel, Tinkal C and Solu, Mahesh G and Patel, Jitendra and Shah, Yash R and Jarag, Mayur and Godbole, Varsha and Shah, Meenakshi and Raj, Rikin and Nagori, Irfan and Jha, Pramod R and Shah, Arti D and Yeeli, Gowtham and Jain, Archit and Gill, Rooppreet Kaur and Babu, KV Sreedhar and Babu, B Suresh and Mohan, Alladi and Vengamma, B and Sekhar, K Chandra and Damam, Srinivasulu and Narsimhulu, K and Aparna, C and Baleswari, G and Ravindranath, Reddy K and Chandrasekhar, P and Panjwani, Sunil Jodharam and Akholkar, Pankaj J. and Joshi, Kairavi Parthesh and Shah, Pragnesh H. and Barvaliya, Manish and Baldi, Milind and Yadav, Ashok and Gupta, Manoj and Rawat, Nitin and Chawda, Dilip and Natarajan, M and Sintha, M and Kumar, David Pradeep and Rabbani, Fathhur and Khadke, Vrushali Khirid and Patki, Dattatray and Marathe, Sonali and D{\textquoteright}Souza, Clyde and Tadha, Vipul and Arora, Satyam and Gupta, Devendra Kumar and Dua, Seema and Chauhan, Nitu and Chahar, Ajeet Singh and Mammen, Joy John and Kumar, Snehil and Daniel, Dolly and Singh, Ravindraa and Dhat, Venkatesh and Agarwal, Yogesh and Arora, Sohini and Pathak, Ashish and Purohit, Manju and Sharma, Ashish and Sharma, Jayashree and Madkaikar, Manisha and Joshi, Kavita and Yadav, Reetika Malik and Bhagwat, Swarupa and Karnik, Niteen D and Gokhale, Yojana A and Naik, Leena and Margam, Sangita and Das, Santasabuj and Turuk, Dr Alka and Kumar, V Saravana and Kanagasabai, K and Sabarinathan, R and Deshpande, Gururaj and Sharma, Sharda and Gunjikar, Rashmi and Shete, Anita and Phagiwala, Darpan and Patil, Chetan and Shingade, Snehal and Jarande, Kajal and Kaushal, Himanshu and Yadav, Pragya D and Sapkal, Gajanan and Abraham, Priya}, title = {Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial)}, elocation-id = {2020.09.03.20187252}, year = {2020}, doi = {10.1101/2020.09.03.20187252}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Objectives Convalescent plasma (CP) as a passive source of neutralizing antibodies and immunomodulators is a century-old therapeutic option used for the management of viral diseases. We investigated its effectiveness for the treatment of COVID-19.Design Open-label, parallel-arm, phase II, multicentre, randomized controlled trial.Setting Thirty-nine public and private hospitals across India.Participants Hospitalized, moderately ill confirmed COVID-19 patients (PaO2/FiO2: 200-300 or respiratory rate \> 24/min and SpO2 <= 93\% on room air).Intervention Participants were randomized to either control (best standard of care (BSC)) or intervention (CP + BSC) arm. Two doses of 200 mL CP was transfused 24 hours apart in the intervention arm.Main Outcome Measure Composite of progression to severe disease (PaO2/FiO2\< 100) or all-cause mortality at 28 days post-enrolment.Results Between 22nd April to 14th July 2020, 464 participants were enrolled; 235 and 229 in intervention and control arm, respectively. Composite primary outcome was achieved in 44 (18.7\%) participants in the intervention arm and 41 (17.9\%) in the control arm [aOR: 1.09; 95\% CI: 0.67, 1.77]. Mortality was documented in 34 (13.6\%) and 31 (14.6\%) participants in intervention and control arm, respectively [aOR) 1.06 95\% CI: -0.61 to 1.83].Interpretation CP was not associated with reduction in mortality or progression to severe COVID-19. This trial has high generalizability and approximates real-life setting of CP therapy in settings with limited laboratory capacity. A priori measurement of neutralizing antibody titres in donors and participants may further clarify the role of CP in management of COVID-19.Trial registration The trial was registered with Clinical Trial Registry of India (CTRI); CTRI/2020/04/024775.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare that TB is a member of the National Task Force for COVID-19 which approved the protocol. AM, AA, GK, AT, TB, VS, KK, RS, SD, GD, SS, RG, AS, DP, CP, SS, KJ, HK, PDY, GS, PA, MM, RMY are employed with ICMR, the funding source for the trial. PC was an employee of ICMR during the trial. The funding source (ICMR) has no financial interest in the investigational product. No other author has any competing financial or non-financial interest.Clinical TrialCTRI/2020/04/024775Funding StatementThis multi-centric study was funded by ICMR, an autonomous Government-funded medical research council. The National Task Force for COVID-19, a committee formed by ICMR to respond to the pandemic has reviewed and approved this study. The Central Implementation Team at ICMR was responsible for study design, study coordination, data analysis, data interpretation and writing of the report. Patient enrolment, data collection and actual conduct of the study was done at public and private hospitals independently and the investigators in ICMR had no role in it. The funding source has no financial interest in the investigational product. The corresponding author at ICMR had access to all the data, is the guarantor for the current work and holds final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics comittee at the Indian council Medical Research, India and Intitutional review boards of all participating institutes.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual patient level data, collected in connection with the PLACID Trial, along with a data dictionary defining the variable fields has been developed and is available with the corresponding author. De-identified participant level data with data dictionary, or a sub-set thereof, may be made available upon written request to the corresponding author. Additional documents, including the study protocol, statistical analysis plan have been made available as supplementary files within the original submission. Results of secondary or sub-group analyses will be provided on request. Data will be made available, upon request once the trial is published. Data requests should be accompanied by a brief proposal outlining the analysis plan, which may be carried out with investigator support. A signed data access agreement may be needed to ensure data safety and compliance with national rules regarding data sharing.}, URL = {https://www.medrxiv.org/content/early/2020/09/08/2020.09.03.20187252}, eprint = {https://www.medrxiv.org/content/early/2020/09/08/2020.09.03.20187252.full.pdf}, journal = {medRxiv} }